e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
Collard Harold R.
Source:
Eur Respir J 2015; 45: 1218-1220
Journal Issue:
May
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Collard Harold R.. Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1218-1220
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Acute exacerbations of IPF: A neglected threat in IPF ?
Related content which might interest you:
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Year: 2017
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Idiopathic pulmonary fibrosis: present understanding and future options
Source: Eur Respir Rev 2011; 20: 132-133
Year: 2011
The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Potential new biomarkers for idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour
Source: Eur Respir J 2007; 30: Suppl. 51, 488s
Year: 2007
Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Idiopathic pulmonary fibrosis: recent milestones in disease management
Source: Eur Respir Rev 2012; 21: 140
Year: 2012
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept